ANTI-HIV TYPE-1 CYTOTOXIC T-LYMPHOCYTE EFFECTOR ACTIVITY AND DISEASE PROGRESSION IN THE FIRST 8 YEARS OF HIV TYPE-1 INFECTION OF HOMOSEXUAL MEN

被引:54
作者
RINALDO, CR
BELTZ, LA
HUANG, XL
GUPTA, P
FAN, Z
TORPEY, DJ
机构
[1] UNIV PITTSBURGH,SCH MED,DEPT PATHOL,PITTSBURGH,PA 15261
[2] UNIV PITTSBURGH,SCH MED,DEPT INFECT DIS & MICROBIOL,PITTSBURGH,PA 15261
关键词
D O I
10.1089/aid.1995.11.481
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cytotoxic T lymphocytes (CTL) may play an important role in host defense against HIV-1 infection, In this study, we examined the responses of circulating effector CTL (CTLe) specific for Gag, Pol, Env, and Tat in 57 HIV-1-infected men, 49 of whom were asymptomatic and had documented time since seroconversion of <8 years, CTLe responses to at least one of the four HIV-1 gene products were detected in 83% of the subjects, The magnitude and prevalence of the anti-Tat responses were significantly less than the responses to Gag, pol, and Env. Cell depletion studies indicated that the lytic activity against the HIV-1 structural proteins was mediated by CD8(+) T cells, although 30% of Env-specific lysis was mediated by CD16(+) natural killer cells, Anti-HIV-1 CTLe responses against Gag and Pol were significantly less in subjects infected for over 6 years as compared to those infected for shorter periods of time, We found no correlation, however, between anti-HIV-1 CTLe responses and either CD4(+) or CD8(+) T cell counts, rates of CD4(+) T cell loss, HIV-1 infectious viral load, use of antiviral medications, or subsequent progression to AIDS, Our results indicate that anti-HIV-1 CTLe activity is relatively stable in asymptomatic subjects infected <6 years, and is not an early marker for risk of disease progression.
引用
收藏
页码:481 / 489
页数:9
相关论文
共 42 条
[1]   VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
BORROW, P ;
LEWICKI, H ;
HAHN, BH ;
SHAW, GM ;
OLDSTONE, MBA .
JOURNAL OF VIROLOGY, 1994, 68 (09) :6103-6110
[2]  
BUSEYNE F, 1993, J IMMUNOL, V150, P3569
[3]   HIV-SPECIFIC CD8+ T-CELL IMMUNE-RESPONSES AND VIRAL REPLICATION [J].
BUSEYNE, F ;
RIVIERE, Y .
AIDS, 1993, 7 :S81-S85
[4]   QUANTITATIVE-ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOTOXIC LYMPHOCYTE-T (CTL) RESPONSE AT DIFFERENT STAGES OF HIV-1 INFECTION - DIFFERENTIAL CTL RESPONSES TO HIV-1 AND EPSTEIN-BARR-VIRUS IN LATE DISEASE [J].
CARMICHAEL, A ;
JIN, X ;
SISSONS, P ;
BORYSIEWICZ, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :249-256
[5]   EXPRESSION OF THE HTLV-III ENVELOPE GENE BY A RECOMBINANT VACCINIA VIRUS [J].
CHAKRABARTI, S ;
ROBERTGUROFF, M ;
WONGSTAAL, F ;
GALLO, RC ;
MOSS, B .
NATURE, 1986, 320 (6062) :535-537
[6]   CYTOTOXIC LYMPHOCYTE-T RESPONSES IN THE PERIPHERAL-BLOOD OF CHILDREN BORN TO HUMAN IMMUNODEFICIENCY VIRUS-1-INFECTED MOTHERS [J].
CHEYNIER, R ;
LANGLADEDEMOYEN, P ;
MARESCOT, MR ;
BLANCHE, S ;
BLONDIN, G ;
WAINHOBSON, S ;
GRISCELLI, C ;
VILMER, E ;
PLATA, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (09) :2211-2217
[7]  
DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123
[8]   USE OF VACCINIA VIRUS VECTORS TO STUDY THE SYNTHESIS, INTRACELLULAR-LOCALIZATION, AND ACTION OF THE HUMAN IMMUNODEFICIENCY VIRUS TRANS-ACTIVATOR PROTEIN [J].
FALKNER, FG ;
FUERST, TR ;
MOSS, B .
VIROLOGY, 1988, 164 (02) :450-457
[9]   QUALITY-CONTROL IN THE FLOW CYTOMETRIC MEASUREMENT OF LYMPHOCYTE-T SUBSETS - THE MULTICENTER AIDS COHORT STUDY EXPERIENCE [J].
GIORGI, JV ;
CHENG, HL ;
MARGOLICK, JB ;
BAUER, KD ;
FERBAS, J ;
WAXDAL, M ;
SCHMID, I ;
HULTIN, LE ;
JACKSON, AL ;
PARK, L ;
TAYLOR, JMG .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1990, 55 (02) :173-186
[10]   EXPRESSION AND PROCESSING OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 GAG AND POL GENES BY CELLS INFECTED WITH A RECOMBINANT VACCINIA VIRUS [J].
GOWDA, SD ;
STEIN, BS ;
STEIMER, KS ;
ENGLEMAN, EG .
JOURNAL OF VIROLOGY, 1989, 63 (03) :1451-1454